After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
The FDA has approved a new option for HIV-1 pre-exposure prophylaxis to reduce HIV-1 infection risk from sex, excluding in those who have receptive vaginal sex.
The FDA has approved a new option for HIV-1 pre-exposure prophylaxis to reduce HIV-1 infection risk from sex, excluding in those who have receptive vaginal sex.
The FDA has approved a type 2 diabetes medication for the reduction of risk of end-stage kidney disease and cardiovascular events in adults with type 2 diabetes and diabetic kidney disease.
The FDA has approved a new option for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children aged 2 years and older.
The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...
